Advertisement


Arnon P. Kater, MD, PhD, on CLL: Efficacy of Venetoclax in Relapsed or Refractory Disease

EHA25 Virtual

Advertisement

Arnon P. Kater, MD, PhD, of the University of Amsterdam, Cancer Center Amsterdam, discusses phase IIIb results from the VENICE I trial, which confirmed that venetoclax monotherapy can achieve deep responses and has a tolerable and manageable safety profile in patients with relapsed or refractory chronic lymphocytic leukemia (Abstract S156).



Related Videos

Leukemia
Geriatric Oncology

Andrew H. Wei, MBBS, PhD, on AML: Venetoclax Plus Cytarabine in Older Patients

Andrew H. Wei, MBBS, PhD, of The Alfred Hospital, Monash University, discusses phase III data from the VIALE-C trial, which appear to support the use of venetoclax plus low-d...

Leukemia

Abhishek Maiti, MBBS, on AML: Decitabine and Venetoclax vs Intensive Chemotherapy

Abhishek Maiti, MBBS, of The University of Texas MD Anderson Cancer Center, discusses his analysis showing that 10-day decitabine and venetoclax led to superior outcomes comp...

Leukemia
Lymphoma

Elias Jabbour, MD, on Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma: Venetoclax and Navitoclax in Relapsed or Refractory Disease

Elias Jabbour, MD, of The University of Texas MD Anderson Cancer Center, discusses study findings that showed venetoclax and navitoclax with chemotherapy is well tolerated, w...

Leukemia
Lymphoma

John C. Byrd, MD, on CLL/SLL: Acalabrutinib in Treatment-Naive Patients

John C. Byrd, MD, of The Ohio State University Comprehensive Cancer Center, discusses the mature results of a phase II study showing durable remissions and long-term tolerabi...

Leukemia

Jorge E. Cortes, MD, on Chronic Phase CML: Comparing Three Starting Doses of Ponatinib

Jorge E. Cortes, MD, of Georgia Cancer Center, discusses interim results from the OPTIC study, which showed a trend toward dose-dependent efficacy and safety, and may provide...

Advertisement

Advertisement



Advertisement